NNBP - Nanobac Pharmaceuticals - 500 Beiträge pro Seite

[MultiCash]

an der Nasdaq unter NNBP gelistet

Nanobac is in the business of pharmaceutical drug research and development, research and development of medical diagnostics, nanobiotechnology and nanotechnology; all related to the emerging infectious disease pathogen known as Nanobacterium sanguineum ("Nanobacteria") that has been shown to be a cause of atherosclerotic coronary artery calcified plaque, and other calcifications found in human diseases.

Nanobac`s intellectual property consists of US Patents and Patents Pending relating to the isolation of Nanobacteria, diagnostic methods and prescription nanobiotic® treatment preparations. In 2000, NanobacLabs successfully completed an observational clinical trial, the NanobacTX® Pilot Study using its nanobiotic® preparation, NanobacTX®. In this Pilot Study of 90 patients with documented coronary artery calcification as determined by Computed Tomography with coronary artery calcification scoring system ("heartscan"), a treatment-time-dependent regression of coronary artery calcification scores was seen, suggesting regression of atherosclerotic plaque in the coronary arteries.

The NanobacTX® Pilot Study was followed by the NanobacTX-ACES Multicenter Study involving hundreds of physician investigators. A formal Independent Review Board approved study, the NanobacTX-ACESII Cardiology Study, was conducted by Cardiologist Benedict S. Maniscalco, MD, FACC using the nanobiotic® NanobacTX®in 100 patients with well-documented calcified atherosclerotic coronary artery heart disease. Dr. Maniscalco`s Study results were submitted for publication in May, 2003. Dr. Maniscalco is scheduled to present his clinical trial findings at the Annual Meeting of the American College of Cardiology-Florida Chapter in August. An Abstract of his findings was submitted to the American Heart Association for oral presentation at the 2003 Scientific Sessions to be held November 9-12, 2003 in Orlando, FL.

Nanobac derives revenue from its prescription nanobiotics® NanobacTX® and UroBac® that are marketed to physicians and researchers worldwide. For more information about Nanobac, visit the website: http://www.nanobaclabs.com .

[isonics]

Im aktuellen Nanotech-Report steht etwas über Nanobac. Die haben wohl gerade vor ein paar Tagen ihren Namen geändert!
Die Bewertung vom Nanotech-Report: Chance=5 Risiko=5 (also jeweils volle Punktzahl)

Das Unternehmen gefällt mir ganz gut, werde mir welche ins Depot legen!

Isonics

[www.aktieninsel.de]

Habe nirgends die Marktkapitalisierung finden können, wisst Ihr wie hoch die ist?

[isonics]

Hallo Aktieninsel,
bei bigcharts.com findet man sie:

Shares Outstanding: 37,650,000
Market Cap: 30.1 Million

Grüße

Isonics